1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
David A. Braun, MD, PhD
Medical Oncology, Genitourinary Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Titles
- Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- R37 MERIT Award: National Institutes of Health / National Cancer Institute (NIH/NCI) (2023)
- Idea Development Award: Department of Defense (2023)
- Young Physician-Scientist Award: American Society of Clinical Investigation (ASCI) (2023)
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Yochum Z, Braun D. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. The Lancet 2024, 404: 1280-1282. PMID: 39284326, DOI: 10.1016/s0140-6736(24)01866-x.
- Figiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, Milowsky M, Mitchell T, Bryant R, Sfakianos J, Lamb A. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology 2024 PMID: 39227262, DOI: 10.1016/j.eururo.2024.08.025.
- Saliby R, Xie W, Wells J, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Rodriguez C, Ruiz J, Powles T, Wood L, De Velasco Oria G, Takemura K, Braun D, Heng D, Choueiri T. 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. Annals Of Oncology 2024, 35: s1021-s1022. DOI: 10.1016/j.annonc.2024.08.1797.
- Braun D, Wang Y, Yu A, Pickering C, Serie D, Choueiri T, Xu W, Sun M, Vemula S, Gupta S. 1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER. Annals Of Oncology 2024, 35: s1012-s1013. DOI: 10.1016/j.annonc.2024.08.1787.
- Nawfal R, Semaan K, Eid M, Paul M, Saliby R, Chehade R, Machaalani M, Saad E, Phillips N, Canniff J, Vasseur D, Zarif T, Yekeduz E, Sun M, Baca S, Braun D, Xie W, Krajewski K, Choueiri T. 1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens. Annals Of Oncology 2024, 35: s1022-s1023. DOI: 10.1016/j.annonc.2024.08.1798.
- McGregor B, Paul M, Xie W, Xu W, Bilen M, Braun D, Berg S, Zhang T, McKay R, McDermott D, Hammers H, Choueiri T. 1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh). Annals Of Oncology 2024, 35: s1020. DOI: 10.1016/j.annonc.2024.08.1795.
- Machaalani M, Chehade R, Nassar A, Zarif T, Saad E, Yekeduz E, Saliby R, Steiner C, Nawfal R, Semaan K, Eid M, Lee G, Pomerantz M, McKay R, Tarantino P, Braun D, Sun M, Tolaney S, Choueiri T. 176P ERBB2 amplifications across sex, race, and cancer types. Annals Of Oncology 2024, 35: s285-s286. DOI: 10.1016/j.annonc.2024.08.2181.
- Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 1-12. PMID: 39169264, DOI: 10.1038/s41587-024-02348-3.
- El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen C, Alva A, Fahey C, Beckermann K, Karam J, Campbell M, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney H, De Giorgi U, Parikh O, Winquist E, Master V, Garcia A, Cutuli H, Ferguson T, Gross-Goupil M, Baca S, Pal S, Braun D, McKay R, Heng D, Choueiri T. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. European Urology 2024 PMID: 39147674, DOI: 10.1016/j.eururo.2024.07.016.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- Semaan K, Zarif T, Eid M, Canniff J, Phillips N, Fortunato B, Savignano H, Davidson M, Chehade R, Garinet S, Saad E, Saliby R, Sun M, Seo J, Berchuck J, Braun D, Freedman M, Choueiri T, Baca S. 44 Liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma. The Oncologist 2024, 29: s4-s5. PMCID: PMC11301903, DOI: 10.1093/oncolo/oyae181.006.
- Yekeduz E, Braun D, Chehade R, Eid M, Labaki C, Machaalani M, Nassar A, Nawfal R, Saad E, Saliby R, Semaan K, Sun M, Hirsch M, Ürün Y, Zarif T, Choueiri T. 24 Applying genomic analysis to refine unclassified renal cell carcinoma. The Oncologist 2024, 29: s20-s20. PMCID: PMC11301928, DOI: 10.1093/oncolo/oyae181.032.
- Saliby R, Xie W, Wells C, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Ravi P, Suarez C, Morales J, McKay R, Powles T, Wood L, Lalani A, Pal S, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. The Oncologist 2024, 29: s8-s9. PMCID: PMC11301915, DOI: 10.1093/oncolo/oyae181.013.
- Saad E, Mehrabad E, Labaki C, Saliby R, Semaan K, Eid M, Machaalani M, Chehade R, Nawfal R, Sun M, Sharon E, Shah P, Vemula S, Gupta S, Braun D, Van Allen E, Gusev A, Choueiri T. 22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs). The Oncologist 2024, 29: s1-s2. PMCID: PMC11301885, DOI: 10.1093/oncolo/oyae181.003.
- Nawfal R, Eid M, Semaan K, Paul M, Saliby R, Chehade R, Machaalani M, Phillips N, Canniff J, Saad E, Vasseur D, Zarif T, Yekeduz E, Sun M, Baca S, Braun D, Xie W, Krajewski K, Choueiri T. 46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens. The Oncologist 2024, 29: s25-s26. PMCID: PMC11301862, DOI: 10.1093/oncolo/oyae181.041.
- Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.
- Moritz V, Xu W, Birch G, Meliki A, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. 14 Natural killer cells have impaired cytotoxicity in advanced renal cell carcinoma. The Oncologist 2024, 29: s7-s8. PMCID: PMC11301877, DOI: 10.1093/oncolo/oyae181.012.
- PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?Bakouny Z, Braun D, Reznik E, Hakimi A. PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy? EBioMedicine 2024, 105: 105218. PMID: 38924842, PMCID: PMC11259692, DOI: 10.1016/j.ebiom.2024.105218.
- El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, DOI: 10.1016/j.celrep.2024.114350.
- Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, Braun D, Chen Y. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society Of Clinical Oncology Educational Book 2024, 44: e438658. PMID: 38875505, DOI: 10.1200/edbk_438658.
- Serzan M, Jegede O, Alter R, Bilen M, Braun D, Einstein D, Haas N, Herchenhorn D, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Signoretti S, CHOUEIRI T, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps4614-tps4614. DOI: 10.1200/jco.2024.42.16_suppl.tps4614.
- Nabil Laimon Y, Paul M, Ghandour F, El Ahmar N, Matar S, Denize T, Bagheri Sheshdeh A, Savla V, Mohanna R, Sun M, Saliby R, Saad E, Machaalani M, Braun D, Aftab D, Xie W, CHOUEIRI T, Signoretti S. Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial. Journal Of Clinical Oncology 2024, 42: 4543-4543. DOI: 10.1200/jco.2024.42.16_suppl.4543.
- Matar S, Jegede O, Denize T, Ghandour F, Nabil Laimon Y, El Ahmar N, Bagheri Sheshdeh A, Savla V, Mohanna R, Catalano P, Braun D, Sun M, Gupta S, Vemula S, Freeman G, Motzer R, Atkins M, McDermott D, CHOUEIRI T, Signoretti S. Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial. Journal Of Clinical Oncology 2024, 42: 4536-4536. DOI: 10.1200/jco.2024.42.16_suppl.4536.
- Zaemes J, Hugaboom M, Shah V, Haas N, McDermott D, Jegede O, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Hurwitz M, Wu C, Einstein D, Hammers H, Signoretti S, West D, Denize T, Atkins M, Braun D. Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). Journal Of Clinical Oncology 2024, 42: 4546-4546. DOI: 10.1200/jco.2024.42.16_suppl.4546.
- Yekeduz E, Braun D, El Hajj Chehade R, Eid M, Labaki C, Machaalani M, Nassar A, Nawfal R, Saad E, Saliby R, Semaan K, Sun M, Hirsch M, Ürün Y, El Zarif T, CHOUEIRI T. Applying genomic analysis to refine unclassified renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 4551-4551. DOI: 10.1200/jco.2024.42.16_suppl.4551.
- Saliby R, Semaan K, Epstein I, Liria S, Dall C, Saad E, Eid M, Canniff J, Kwak L, Berg S, Mantia C, McGregor B, Braun D, CHOUEIRI T, Bellmunt J. Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3. Journal Of Clinical Oncology 2024, 42: e16570-e16570. DOI: 10.1200/jco.2024.42.16_suppl.e16570.
- Kashima S, Ye Z, Meliki A, Hugaboom M, Schindler N, Graham J, Moritz V, El Ahmar N, Nabil Laimon Y, Canniff J, Saliby R, Lee G, Machaalani M, Sun M, Xu W, Signoretti S, McGregor B, McKay R, CHOUEIRI T, Braun D. Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 4515-4515. DOI: 10.1200/jco.2024.42.16_suppl.4515.
- Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.
- Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
- Serzan M, Jegede O, Bilen M, Braun D, Einstein D, Haas N, Hammers H, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Choueiri T, Signoretti S, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps492-tps492. DOI: 10.1200/jco.2024.42.4_suppl.tps492.
- Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.
- Saad E, Labaki C, Miron B, Park J, Bakouny Z, Nassar A, Saliby R, Semaan K, Eid M, Meli K, Nabil Laimon Y, Geynisman D, Kokate R, Braun D, Signoretti S, McGregor B, Plimack E, Choueiri T, Van Allen E, Zibelman M. Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 459-459. DOI: 10.1200/jco.2024.42.4_suppl.459.
- Semaan K, El Zarif T, Seo J, Eid M, Canniff J, Fortunato B, Savignano H, Davidsohn M, Lakshminarayanan G, Saad E, Saliby R, Bakouny Z, Matar S, Nuzzo P, Berchuck J, Signoretti S, Braun D, Freedman M, Baca S, Choueiri T. Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation. Journal Of Clinical Oncology 2024, 42: 449-449. DOI: 10.1200/jco.2024.42.4_suppl.449.
- El Ahmar N, Matar S, Jegede O, Nabil Laimon Y, Savla V, Bagheri Sheshdeh A, Denize T, Mohanna R, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2024, 42: 448-448. DOI: 10.1200/jco.2024.42.4_suppl.448.
- Saliby R, Xie W, Wells J, Saad E, Eid M, Labaki C, Semaan K, Ferrier E, Lemelin A, Suárez C, Ruiz-Morales J, Powles T, Wood L, Ebrahimi H, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study. Journal Of Clinical Oncology 2024, 42: 400-400. DOI: 10.1200/jco.2024.42.4_suppl.400.
- Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
- Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, Bagheri A, Savla V, Nabil Laimon Y, Gupta S, Vemula S, Braun D, Burke K, Catalano P, Freeman G, Motzer R, Atkins M, McDermott D, Sharpe A, Choueiri T, Signoretti S. PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients. Clinical Cancer Research 2024, 30: 803-813. PMID: 38060202, PMCID: PMC10922154, DOI: 10.1158/1078-0432.ccr-23-2274.
- Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.
- Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
- McKay R, Leucht K, Xie W, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. The Oncologist 2023, 29: 324-331. PMID: 37950901, PMCID: PMC10994246, DOI: 10.1093/oncolo/oyad298.
- Kashima S, Soulati H, Madsen K, Sadak K, Wirth L, Hurwitz M, Kluger H, Sznol M, Humphrey P, Adeniran A, Kenney P, Braun D. 542 TIGIT as a potential therapeutic target in renal cell carcinoma. 2023, a616-a616. DOI: 10.1136/jitc-2023-sitc2023.0542.
- Hugaboom M, Street K, Ruthen N, Wirth L, Jegede O, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. 1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma. 2023, a1125-a1125. DOI: 10.1136/jitc-2023-sitc2023.1017.
- Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, Hari S, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun D, Rodig S, Choueiri T, Signoretti S, Van Allen E. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Reports Medicine 2023, 4: 101189. PMID: 37729872, PMCID: PMC10518628, DOI: 10.1016/j.xcrm.2023.101189.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.
- Henske E, Cheng L, Hakimi A, Choueiri T, Braun D. Chromophobe renal cell carcinoma. Cancer Cell 2023, 41: 1383-1388. PMID: 37541245, DOI: 10.1016/j.ccell.2023.07.006.
- Labaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
- Anderson K, Braun D, Buqué A, Gitto S, Guerriero J, Horton B, Keenan B, Kim T, Overacre-Delgoffe A, Ruella M, Triplett T, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For ImmunoTherapy Of Cancer 2023, 11: e006533. PMID: 37399356, PMCID: PMC10314654, DOI: 10.1136/jitc-2022-006533.
- Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.
- Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.
- Saliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.
- Braun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.
- Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.
- Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
- Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, Fonseca M, Spisak S, El Zarif T, Tisza V, Braun D, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar S, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck J, O’Connor E, Bell C, Nuzzo P, Mary Lee G, Signoretti S, Hirsch M, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri T, Kwiatkowski D, Freedman M. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications 2023, 14: 346. PMID: 36681680, PMCID: PMC9867739, DOI: 10.1038/s41467-023-35833-5.
- Groha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.
- Oliveira G, Stromhaug K, Cieri N, Iorgulescu J, Klaeger S, Wolff J, Rachimi S, Chea V, Krause K, Freeman S, Zhang W, Li S, Braun D, Neuberg D, Carr S, Livak K, Frederick D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon C, Keskin D, Ott P, Rodig S, Boland G, Wu C. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022, 605: 532-538. PMID: 35508657, PMCID: PMC9815755, DOI: 10.1038/s41586-022-04682-5.
- Liu S, Iorgulescu J, Li S, Barrera-Lopez I, Borji M, Shanmugam V, Morriss J, Garcia Z, Murray E, Braun D, Livak K, Wu C, Chen F. Spatially mapping T cell receptors and transcriptomes. The Journal Of Immunology 2022, 208: 172.01-172.01. DOI: 10.4049/jimmunol.208.supp.172.01.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait. New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Locations
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
Titles
- Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- R37 MERIT Award: National Institutes of Health / National Cancer Institute (NIH/NCI) (2023)
- Idea Development Award: Department of Defense (2023)
- Young Physician-Scientist Award: American Society of Clinical Investigation (ASCI) (2023)
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Yochum Z, Braun D. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. The Lancet 2024, 404: 1280-1282. PMID: 39284326, DOI: 10.1016/s0140-6736(24)01866-x.
- Figiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, Milowsky M, Mitchell T, Bryant R, Sfakianos J, Lamb A. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology 2024 PMID: 39227262, DOI: 10.1016/j.eururo.2024.08.025.
- Saliby R, Xie W, Wells J, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Rodriguez C, Ruiz J, Powles T, Wood L, De Velasco Oria G, Takemura K, Braun D, Heng D, Choueiri T. 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. Annals Of Oncology 2024, 35: s1021-s1022. DOI: 10.1016/j.annonc.2024.08.1797.
- Braun D, Wang Y, Yu A, Pickering C, Serie D, Choueiri T, Xu W, Sun M, Vemula S, Gupta S. 1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER. Annals Of Oncology 2024, 35: s1012-s1013. DOI: 10.1016/j.annonc.2024.08.1787.
- Nawfal R, Semaan K, Eid M, Paul M, Saliby R, Chehade R, Machaalani M, Saad E, Phillips N, Canniff J, Vasseur D, Zarif T, Yekeduz E, Sun M, Baca S, Braun D, Xie W, Krajewski K, Choueiri T. 1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens. Annals Of Oncology 2024, 35: s1022-s1023. DOI: 10.1016/j.annonc.2024.08.1798.
- McGregor B, Paul M, Xie W, Xu W, Bilen M, Braun D, Berg S, Zhang T, McKay R, McDermott D, Hammers H, Choueiri T. 1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh). Annals Of Oncology 2024, 35: s1020. DOI: 10.1016/j.annonc.2024.08.1795.
- Machaalani M, Chehade R, Nassar A, Zarif T, Saad E, Yekeduz E, Saliby R, Steiner C, Nawfal R, Semaan K, Eid M, Lee G, Pomerantz M, McKay R, Tarantino P, Braun D, Sun M, Tolaney S, Choueiri T. 176P ERBB2 amplifications across sex, race, and cancer types. Annals Of Oncology 2024, 35: s285-s286. DOI: 10.1016/j.annonc.2024.08.2181.
- Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 1-12. PMID: 39169264, DOI: 10.1038/s41587-024-02348-3.
- El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen C, Alva A, Fahey C, Beckermann K, Karam J, Campbell M, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney H, De Giorgi U, Parikh O, Winquist E, Master V, Garcia A, Cutuli H, Ferguson T, Gross-Goupil M, Baca S, Pal S, Braun D, McKay R, Heng D, Choueiri T. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. European Urology 2024 PMID: 39147674, DOI: 10.1016/j.eururo.2024.07.016.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- Semaan K, Zarif T, Eid M, Canniff J, Phillips N, Fortunato B, Savignano H, Davidson M, Chehade R, Garinet S, Saad E, Saliby R, Sun M, Seo J, Berchuck J, Braun D, Freedman M, Choueiri T, Baca S. 44 Liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma. The Oncologist 2024, 29: s4-s5. PMCID: PMC11301903, DOI: 10.1093/oncolo/oyae181.006.
- Yekeduz E, Braun D, Chehade R, Eid M, Labaki C, Machaalani M, Nassar A, Nawfal R, Saad E, Saliby R, Semaan K, Sun M, Hirsch M, Ürün Y, Zarif T, Choueiri T. 24 Applying genomic analysis to refine unclassified renal cell carcinoma. The Oncologist 2024, 29: s20-s20. PMCID: PMC11301928, DOI: 10.1093/oncolo/oyae181.032.
- Saliby R, Xie W, Wells C, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Ravi P, Suarez C, Morales J, McKay R, Powles T, Wood L, Lalani A, Pal S, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. The Oncologist 2024, 29: s8-s9. PMCID: PMC11301915, DOI: 10.1093/oncolo/oyae181.013.
- Saad E, Mehrabad E, Labaki C, Saliby R, Semaan K, Eid M, Machaalani M, Chehade R, Nawfal R, Sun M, Sharon E, Shah P, Vemula S, Gupta S, Braun D, Van Allen E, Gusev A, Choueiri T. 22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs). The Oncologist 2024, 29: s1-s2. PMCID: PMC11301885, DOI: 10.1093/oncolo/oyae181.003.
- Nawfal R, Eid M, Semaan K, Paul M, Saliby R, Chehade R, Machaalani M, Phillips N, Canniff J, Saad E, Vasseur D, Zarif T, Yekeduz E, Sun M, Baca S, Braun D, Xie W, Krajewski K, Choueiri T. 46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens. The Oncologist 2024, 29: s25-s26. PMCID: PMC11301862, DOI: 10.1093/oncolo/oyae181.041.
- Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.
- Moritz V, Xu W, Birch G, Meliki A, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. 14 Natural killer cells have impaired cytotoxicity in advanced renal cell carcinoma. The Oncologist 2024, 29: s7-s8. PMCID: PMC11301877, DOI: 10.1093/oncolo/oyae181.012.
- PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?Bakouny Z, Braun D, Reznik E, Hakimi A. PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy? EBioMedicine 2024, 105: 105218. PMID: 38924842, PMCID: PMC11259692, DOI: 10.1016/j.ebiom.2024.105218.
- El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, DOI: 10.1016/j.celrep.2024.114350.
- Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, Braun D, Chen Y. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society Of Clinical Oncology Educational Book 2024, 44: e438658. PMID: 38875505, DOI: 10.1200/edbk_438658.
- Serzan M, Jegede O, Alter R, Bilen M, Braun D, Einstein D, Haas N, Herchenhorn D, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Signoretti S, CHOUEIRI T, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps4614-tps4614. DOI: 10.1200/jco.2024.42.16_suppl.tps4614.
- Nabil Laimon Y, Paul M, Ghandour F, El Ahmar N, Matar S, Denize T, Bagheri Sheshdeh A, Savla V, Mohanna R, Sun M, Saliby R, Saad E, Machaalani M, Braun D, Aftab D, Xie W, CHOUEIRI T, Signoretti S. Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial. Journal Of Clinical Oncology 2024, 42: 4543-4543. DOI: 10.1200/jco.2024.42.16_suppl.4543.
- Matar S, Jegede O, Denize T, Ghandour F, Nabil Laimon Y, El Ahmar N, Bagheri Sheshdeh A, Savla V, Mohanna R, Catalano P, Braun D, Sun M, Gupta S, Vemula S, Freeman G, Motzer R, Atkins M, McDermott D, CHOUEIRI T, Signoretti S. Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial. Journal Of Clinical Oncology 2024, 42: 4536-4536. DOI: 10.1200/jco.2024.42.16_suppl.4536.
- Zaemes J, Hugaboom M, Shah V, Haas N, McDermott D, Jegede O, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Hurwitz M, Wu C, Einstein D, Hammers H, Signoretti S, West D, Denize T, Atkins M, Braun D. Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). Journal Of Clinical Oncology 2024, 42: 4546-4546. DOI: 10.1200/jco.2024.42.16_suppl.4546.
- Yekeduz E, Braun D, El Hajj Chehade R, Eid M, Labaki C, Machaalani M, Nassar A, Nawfal R, Saad E, Saliby R, Semaan K, Sun M, Hirsch M, Ürün Y, El Zarif T, CHOUEIRI T. Applying genomic analysis to refine unclassified renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 4551-4551. DOI: 10.1200/jco.2024.42.16_suppl.4551.
- Saliby R, Semaan K, Epstein I, Liria S, Dall C, Saad E, Eid M, Canniff J, Kwak L, Berg S, Mantia C, McGregor B, Braun D, CHOUEIRI T, Bellmunt J. Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3. Journal Of Clinical Oncology 2024, 42: e16570-e16570. DOI: 10.1200/jco.2024.42.16_suppl.e16570.
- Kashima S, Ye Z, Meliki A, Hugaboom M, Schindler N, Graham J, Moritz V, El Ahmar N, Nabil Laimon Y, Canniff J, Saliby R, Lee G, Machaalani M, Sun M, Xu W, Signoretti S, McGregor B, McKay R, CHOUEIRI T, Braun D. Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 4515-4515. DOI: 10.1200/jco.2024.42.16_suppl.4515.
- Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.
- Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
- Serzan M, Jegede O, Bilen M, Braun D, Einstein D, Haas N, Hammers H, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Choueiri T, Signoretti S, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps492-tps492. DOI: 10.1200/jco.2024.42.4_suppl.tps492.
- Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.
- Saad E, Labaki C, Miron B, Park J, Bakouny Z, Nassar A, Saliby R, Semaan K, Eid M, Meli K, Nabil Laimon Y, Geynisman D, Kokate R, Braun D, Signoretti S, McGregor B, Plimack E, Choueiri T, Van Allen E, Zibelman M. Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 459-459. DOI: 10.1200/jco.2024.42.4_suppl.459.
- Semaan K, El Zarif T, Seo J, Eid M, Canniff J, Fortunato B, Savignano H, Davidsohn M, Lakshminarayanan G, Saad E, Saliby R, Bakouny Z, Matar S, Nuzzo P, Berchuck J, Signoretti S, Braun D, Freedman M, Baca S, Choueiri T. Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation. Journal Of Clinical Oncology 2024, 42: 449-449. DOI: 10.1200/jco.2024.42.4_suppl.449.
- El Ahmar N, Matar S, Jegede O, Nabil Laimon Y, Savla V, Bagheri Sheshdeh A, Denize T, Mohanna R, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2024, 42: 448-448. DOI: 10.1200/jco.2024.42.4_suppl.448.
- Saliby R, Xie W, Wells J, Saad E, Eid M, Labaki C, Semaan K, Ferrier E, Lemelin A, Suárez C, Ruiz-Morales J, Powles T, Wood L, Ebrahimi H, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study. Journal Of Clinical Oncology 2024, 42: 400-400. DOI: 10.1200/jco.2024.42.4_suppl.400.
- Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
- Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, Bagheri A, Savla V, Nabil Laimon Y, Gupta S, Vemula S, Braun D, Burke K, Catalano P, Freeman G, Motzer R, Atkins M, McDermott D, Sharpe A, Choueiri T, Signoretti S. PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients. Clinical Cancer Research 2024, 30: 803-813. PMID: 38060202, PMCID: PMC10922154, DOI: 10.1158/1078-0432.ccr-23-2274.
- Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.
- Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
- McKay R, Leucht K, Xie W, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. The Oncologist 2023, 29: 324-331. PMID: 37950901, PMCID: PMC10994246, DOI: 10.1093/oncolo/oyad298.
- Kashima S, Soulati H, Madsen K, Sadak K, Wirth L, Hurwitz M, Kluger H, Sznol M, Humphrey P, Adeniran A, Kenney P, Braun D. 542 TIGIT as a potential therapeutic target in renal cell carcinoma. 2023, a616-a616. DOI: 10.1136/jitc-2023-sitc2023.0542.
- Hugaboom M, Street K, Ruthen N, Wirth L, Jegede O, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. 1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma. 2023, a1125-a1125. DOI: 10.1136/jitc-2023-sitc2023.1017.
- Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, Hari S, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun D, Rodig S, Choueiri T, Signoretti S, Van Allen E. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Reports Medicine 2023, 4: 101189. PMID: 37729872, PMCID: PMC10518628, DOI: 10.1016/j.xcrm.2023.101189.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.
- Henske E, Cheng L, Hakimi A, Choueiri T, Braun D. Chromophobe renal cell carcinoma. Cancer Cell 2023, 41: 1383-1388. PMID: 37541245, DOI: 10.1016/j.ccell.2023.07.006.
- Labaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
- Anderson K, Braun D, Buqué A, Gitto S, Guerriero J, Horton B, Keenan B, Kim T, Overacre-Delgoffe A, Ruella M, Triplett T, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For ImmunoTherapy Of Cancer 2023, 11: e006533. PMID: 37399356, PMCID: PMC10314654, DOI: 10.1136/jitc-2022-006533.
- Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.
- Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.
- Saliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.
- Braun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.
- Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.
- Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
- Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, Fonseca M, Spisak S, El Zarif T, Tisza V, Braun D, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar S, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck J, O’Connor E, Bell C, Nuzzo P, Mary Lee G, Signoretti S, Hirsch M, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri T, Kwiatkowski D, Freedman M. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications 2023, 14: 346. PMID: 36681680, PMCID: PMC9867739, DOI: 10.1038/s41467-023-35833-5.
- Groha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.
- Oliveira G, Stromhaug K, Cieri N, Iorgulescu J, Klaeger S, Wolff J, Rachimi S, Chea V, Krause K, Freeman S, Zhang W, Li S, Braun D, Neuberg D, Carr S, Livak K, Frederick D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon C, Keskin D, Ott P, Rodig S, Boland G, Wu C. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022, 605: 532-538. PMID: 35508657, PMCID: PMC9815755, DOI: 10.1038/s41586-022-04682-5.
- Liu S, Iorgulescu J, Li S, Barrera-Lopez I, Borji M, Shanmugam V, Morriss J, Garcia Z, Murray E, Braun D, Livak K, Wu C, Chen F. Spatially mapping T cell receptors and transcriptomes. The Journal Of Immunology 2022, 208: 172.01-172.01. DOI: 10.4049/jimmunol.208.supp.172.01.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait. New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Locations
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511